Answers are grounded in this paper and cite their sources.
Identifies jatrophane diterpenoids as antifibrotic agents in liver fibrosis, suggesting new therapeutic pathways.
Liver fibrosis is an urgent clinical condition that lacks effective therapies. In this study, molecular networking-guided fractionation of the medicinal plant Euphorbia hylonoma yielded a focused jatrophane diterpenoid library ( 1 – 32 ), featuring 26 previously undescribed structures. Subsequent antifibrotic screening of this library in TGF-β1-stimulated hepatic stellate cells (HSCs) identified euphylonoid D ( 1 ) as a novel hit, enabling a preliminary structure–activity relationship (SAR) analysis of this class. In a CCl 4 -induced mouse model, 1 significantly alleviated liver fibrosis while exhibiting a favorable safety profile. Mechanistic studies revealed that 1 acts as the first small-molecule inhibitor of Jagged-1 (JAG1), a classic Notch ligand, thereby suppressing Notch signaling, leading to the attenuation of liver fibrosis. These findings not only validate JAG1 as a therapeutic target for liver fibrosis but also highlight 1 as a promising lead for developing novel antifibrotic agents.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: